What question did this study set out to answer?

This analysis aims to evaluate the long-term cost-effectiveness of semaglutide compared to placebo in patients with type 2 diabetes and chronic kidney disease.

January 10, 2026Cardiovascular Diabetology0 citationsOpen Access

Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW

PRPeter RossingGeneral Cardiology MLMorten Lindhardt CTChristian Klyver TikkanenNovo Nordisk (Denmark)

Key Result

Adding semaglutide to standard of care was projected to be highly cost-effective for treating type 2 diabetes and chronic kidney disease in Denmark.

Key Points

This analysis aims to evaluate the long-term cost-effectiveness of semaglutide compared to placebo in patients with type 2 diabetes and chronic kidney disease.
Assessment of cost-effectiveness using data from the FLOW trial.
Comparison of healthcare costs and outcomes between semaglutide and placebo.
Evaluation based on patient characteristics in a Danish healthcare context.
Semaglutide demonstrated a high level of cost-effectiveness over the long term.
Benefits were observed in both type 2 diabetes management and chronic kidney disease outcomes.
Data indicated favorable treatment effects based on the FLOW trial results.

Structured PICO

Is once-weekly semaglutide or intensified glucose control cost-effective compared to standard care in patients with type 2 diabetes?

Population

People with type 2 diabetes and chronic kidney disease in Denmark (per abstract) and 421,000 people with type 2 diabetes in Sweden (per full text model).

Intervention

Once-weekly semaglutide added to standard of care (abstract) / Intensified glucose control with lower thresholds for treatment intensification (full text).

Comparator

Placebo (abstract) / Usual care (full text).

Outcome

Long-term cost-effectiveness and total costs for healthcare and productivity losses.

Intensified glucose control in type 2 diabetes is projected to be cost-neutral over the long term while significantly reducing cardiovascular and microvascular complications.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Adding semaglutide to SoC was projected to be highly cost-effective over the long term in people with T2D and CKD in a Danish healthcare setting, based on patient characteristics and treatment effects from FLOW. Trial registration NCT03819153, first submitted on January 18, 2019.

Ask AI

Helpful

Bookmark

View Full Paper